Bridging study versus prespecified regions nested in global trials

Drug Information Journal

Volumn 43, Issue 1, 2009, Pages 27-34

  Wang, Sue Jane ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Nested region; Noninferiority; Pharmacogenomics; Subgroup; Two stage adaptive test

Indexed keywords

NEW DRUG;

ANALYTICAL ERROR; ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DRUG RESEARCH; EFFECT SIZE; ETHNIC DIFFERENCE; HUMAN; HYPOTHESIS; INTERNATIONAL COOPERATION; MATHEMATICAL ANALYSIS; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESEARCH SUBJECT; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VARIANCE;

EID: 59849104789     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150904300106     Document Type: Article

References (17)

1. International Conference on Harmonization. Ethnic Factors in the Acceptability of Foreign Clinical Data (ICH E-5). CPMP/ICH/289/95. London: European Agency for the Evaluation of Medicinal Products; 1998.
2. Chern HD. Acceptability of foreign clinical data among Asian countries. Presented at the PhRMA workshop Challenges and Opportunities: Multi-Regional Clinical Trials, Bethesda, Maryland, October 29-30, 2007.
3. Wang SJ, O'Neill RT, Hung HMJ. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat. 2007;6:227-244.
4. Hsiao CL, Chern HD, Chen LK, Lin MS. Algorithm for evaluation of bridging studies in Taiwan. Drug Inf J. 2003;37:123(s)-128(s).
5. Hsiao CF, Wang M, Hsu YY, Liu JP. An overview of bridging evaluations in Taiwan. Int Chinese Stat Assoc Bull. 2005;(January):29-36.
6. Inglefinger JA, Mosteller F, Thibodeau LA, Ware JH. Biostatistics in Clinical Medicine, 2nd ed. New York: Macmillan; 1987.
7. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-control trials. Drug Inf J. 2001;35:435-449.
8. Wang SJ, Hung HMJ, Tsong Y. Utility and pitfalls of some statistical methods in active-controlled clinical trials. Control Clin Trials. 2002;23: 15-28.
9. Snapinn SM. Alternatives for discounting in the analysis of noninferiority trials. J Biopharm Stat. 2004;14:263-273.
10. US Food and Drug Administration. Critical Path opportunities list. March 2006. Available at: http://www.fda.gov/oc/initiatives/criticalPath/.
11. International Conference on Harmonization. Guideline E-5. Ethnic factors in the acceptability of foreign clinical data: questions and answers. CPMP/ICH/5746/03. 2006. Available at: http://www.ich.org/cache/compo/ 276-254-1.html.
12. Wang SJ. Genomic biomarker derived therapeutic effect in pharmacogenomics clinical trials: a biostatistics view of personalized medicine. Taiwan Clin Trials. 2006;4:57-66.
13. Wedel H, DeMets D, Deedwaria P, et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J. 2001;142(3):502-511.
14. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
15. Fukuoka M, Yano S, Glaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2297-2246.
16. Wang SJ. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of Pharmaceutical Statistician Institute (PSI). Pharm Stat. 2007;6:283-296.
17. Hsiao CF, Xu JG, Liu JP. A two-stage design for bridging studies. J Biopharm Stat. 2005;15(1): 75-83.